No Clinically Significant Interaction Between Foundayo and Warfarin
Based on the FDA drug label for Foundayo (orforglipron), there is no documented interaction with warfarin, and no dose adjustments or special monitoring are required when these medications are used together 1.
Evidence Analysis
Direct Drug Interaction Data
The comprehensive drug interaction studies for orforglipron evaluated multiple drug classes and mechanisms, but warfarin was not identified as an interacting medication 1. The FDA label specifically details:
- CYP enzyme effects: Orforglipron does not inhibit or induce CYP2C9 (the primary enzyme responsible for warfarin metabolism) 1
- Transporter effects: No inhibition of relevant transporters that would affect warfarin
- Tested substrates: The drug interaction profile included P-gp substrates (digoxin), CYP3A4 substrates (midazolam), and statins, but no warfarin studies were conducted 1
Mechanistic Considerations
Orforglipron's pharmacologic profile suggests minimal risk for warfarin interaction:
- Not a CYP2C9 inhibitor or inducer: The S-isomer of warfarin (the more potent form) is metabolized by CYP2C9, which orforglipron does not affect 1
- No protein binding displacement: Unlike some drugs that displace warfarin from plasma proteins, this mechanism is not documented for orforglipron
- Gastric emptying delay: While orforglipron delays gastric emptying and can affect absorption rates of other oral medications (demonstrated with acetaminophen showing 28% Cmax reduction after first dose), this effect diminishes with repeated dosing 1
Clinical Context
The comprehensive 2022 warfarin drug interaction guidelines 2 extensively catalog medications that interact with warfarin through various mechanisms (CYP450 inhibition/induction, protein binding displacement, GI absorption interference). Notably, GLP-1 receptor agonists as a class are not mentioned as warfarin-interacting agents, suggesting this is not a class effect concern.
Practical Recommendations
- No dose adjustment needed for either medication when co-administered
- Standard INR monitoring per usual warfarin management protocols is sufficient
- No special timing considerations required for administration
Potential Caveat
The only theoretical consideration is the gastric emptying delay effect during the initial dose escalation phase of Foundayo. However, given that:
- This effect diminishes with repeated dosing 1
- Warfarin has a long half-life (20-60 hours) making it less susceptible to absorption rate changes
- No clinical interaction data suggests concern
Routine co-administration is safe without additional precautions beyond standard warfarin monitoring.